# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
To help facilitate a smooth transition, Bloomer joins the company as executive vice president, finance, effective immediately, ...
On April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain...
First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggre...
The initiative expands the collection of data accessible to Mayo Clinic researchers and clinicians to advance cancer research a...
Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:EXAS) with a Buy and announces $100 price target.
U.S. stocks were lower, with the Dow Jones falling around 400 points on Tuesday.